BiotechTube

BAY 3389934 + Matching Placebo / Diluent

Phase 1Recruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sepsis Associated Disseminated Intravascular Coagulation (DIC)

Conditions

Sepsis Associated Disseminated Intravascular Coagulation (DIC)

Trial Timeline

Sep 22, 2025 → Jan 30, 2026

NCT ID
NCT07176728

About BAY 3389934 + Matching Placebo / Diluent

BAY 3389934 + Matching Placebo / Diluent is a phase 1 stage product being developed by Bayer for Sepsis Associated Disseminated Intravascular Coagulation (DIC). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07176728. Target conditions include Sepsis Associated Disseminated Intravascular Coagulation (DIC).

What happened to similar drugs?

9 of 19 similar drugs in Sepsis Associated Disseminated Intravascular Coagulation (DIC) were approved

Approved (9) Terminated (1) Active (9)
✅MeropenemPfizerApproved
✅ImipenemMerckApproved
✅Drotrecogin Alfa (activated)Eli LillyApproved
✅Drotrecogin alfa (activated)Eli LillyApproved
✅Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved
✅drotrecogin alfa (activated)Eli LillyApproved
✅drotrecogin alfa (activated)Eli LillyApproved

Hype Score Breakdown

Clinical
6
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07176728Phase 1Recruiting

Competing Products

20 competing products in Sepsis Associated Disseminated Intravascular Coagulation (DIC)

See all competitors
ProductCompanyStageHype Score
Alkaline Phosphatase + PlaceboAM-PharmaPhase 2
25
Drotrecogin alfa (activated)Eli LillyPhase 2
35
MeropenemPfizerApproved
43
ImipenemMerckApproved
39
CefiderocolShionogiPhase 1
29
eritoran tetrasodium + PlaceboEisaiPhase 3
40
E5564EisaiPhase 2
35
Drotrecogin Alfa (Activated) + placeboEli LillyPhase 3
40
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
40
Drotrecogin Alfa (activated)Eli LillyApproved
43
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
40
Drotrecogin alfa (activated) + PlaceboEli LillyPhase 3
40
sPLA2 InhibitorEli LillyPhase 1/2
32
Drotrecogin alfa (activated)Eli LillyApproved
43
Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved
43
drotrecogin alfa (activated)Eli LillyApproved
43
drotrecogin alfa (activated)Eli LillyApproved
43
AZD9773 (CytoFab)AstraZenecaPhase 2
35
AZD9773 + PlaceboAstraZenecaPhase 2
35
AZD9773 + PlaceboAstraZenecaPhase 2
35